(Q46788912)

English

Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms

scientific article published on 4 November 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16267634

Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16267634

0 references

1 reference

based on heuristic

inferred from title

object named as

Rolf R Engel

5

0 references

Hans-Jürgen Möller

10

object named as

Hans-Jürgen Möller

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

1

object named as

Michael Riedel

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16267634

Norbert Müller

2

object named as

Norbert Müller

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16267634

author name string

Martin Strassnig

3

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16267634

Ilja Spellmann

4

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16267634

Richard Musil

6

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16267634

Sandra Dehning

7

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16267634

Anette Douhet

8

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16267634

Markus J Schwarz

9

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16267634

publication date

4 November 2005

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16267634

European Archives of Psychiatry and Clinical Neuroscience

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16267634

255

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16267634

6

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16267634

432-437

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16267634

https://scigraph.springernature.com/pub.10.1007/s00406-005-0622-6

0 references

Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study

1 reference

https://api.crossref.org/works/10.1007%2FS00406-005-0622-6

21 January 2018

Determinants of medication compliance in schizophrenia: empirical and clinical findings

1 reference

https://api.crossref.org/works/10.1007%2FS00406-005-0622-6

21 January 2018

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00406-005-0622-6

21 January 2018

Defining treatment refractoriness in schizophrenia.

1 reference

https://api.crossref.org/works/10.1007%2FS00406-005-0622-6

21 January 2018

Quetiapine in schizophrenia: onset of action within the first week of treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/16267634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quetiapine ('Seroquel'); an effective and well-tolerated atypical antipsychotic

1 reference

https://pubmed.ncbi.nlm.nih.gov/16267634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical issues associated with maintenance treatment of patients with schizophrenia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16267634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16267634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mutability and relationship between positive and negative symptoms during neuroleptic treatment in schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/16267634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16267634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Extrapyramidal side effects and tolerability of risperidone: a review

1 reference

https://pubmed.ncbi.nlm.nih.gov/16267634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quetiapine. A review of its use in the management of schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/16267634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atypical neuroleptics: a new approach in the treatment of negative symptoms

1 reference

https://pubmed.ncbi.nlm.nih.gov/16267634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations

1 reference

https://pubmed.ncbi.nlm.nih.gov/16267634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clozapine-induced agranulocytosis. Incidence and risk factors in the United States

1 reference

https://pubmed.ncbi.nlm.nih.gov/16267634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania

1 reference

https://pubmed.ncbi.nlm.nih.gov/16267634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Drug treatment of the negative symptoms of schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/16267634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antipsychotic-induced weight gain: a comprehensive research synthesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16267634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16267634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A rating scale for extrapyramidal side effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/16267634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/16267634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antipsychotic-induced hyperprolactinemia and sexual dysfunction.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16267634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effects of atypical antipsychotics on serum prolactin levels

1 reference

https://pubmed.ncbi.nlm.nih.gov/16267634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adverse events related to olanzapine

1 reference

https://pubmed.ncbi.nlm.nih.gov/16267634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00406-005-0622-6

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16267634

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16267634

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46788912&oldid=2132195810"